Access Bio Inc
Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities wi… Read more
Access Bio Inc (950130) - Total Liabilities
Latest total liabilities as of June 2025: ₩67.08 Billion KRW
Based on the latest financial reports, Access Bio Inc (950130) has total liabilities worth ₩67.08 Billion KRW as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Access Bio Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how Access Bio Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Access Bio Inc Competitors by Total Liabilities
The table below lists competitors of Access Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BayWa AktienGesellschaft Vink.N
F:BYW6
|
Germany | €9.76 Billion |
|
Sparebanken Ost
OL:SPOG
|
Norway | Nkr40.78 Billion |
|
Totens Sparebank
OL:TOTG
|
Norway | Nkr19.83 Billion |
|
Iljin Holdings
KO:015860
|
Korea | ₩984.77 Billion |
|
Solteam Electronics Co Ltd
TWO:3484
|
Taiwan | NT$2.18 Billion |
|
Hansol Paper Co Ltd
KO:213500
|
Korea | ₩1.33 Trillion |
|
Papilon Savunma Guvenlik Sistemleri
IS:PAPIL
|
Turkey | TL43.59 Million |
|
Renascor Resources Ltd
AU:RNU
|
Australia | AU$3.83 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Access Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Access Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Access Bio Inc (2012–2024)
The table below shows the annual total liabilities of Access Bio Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩61.70 Million | -99.94% |
| 2023-12-31 | ₩104.00 Billion | +49192.84% |
| 2022-12-31 | ₩210.97 Million | +60.93% |
| 2021-12-31 | ₩131.10 Million | +64.97% |
| 2020-12-31 | ₩79.47 Million | +103.73% |
| 2019-12-31 | ₩39.01 Million | -24.11% |
| 2018-12-31 | ₩51.40 Million | +11.67% |
| 2017-12-31 | ₩46.03 Million | +5.38% |
| 2016-12-31 | ₩43.68 Million | -98.97% |
| 2015-12-31 | ₩4.24 Billion | -59.04% |
| 2014-12-31 | ₩10.35 Billion | +15.08% |
| 2013-12-31 | ₩8.99 Billion | +21.79% |
| 2012-12-31 | ₩7.38 Billion | -- |